“GC Green Cross announced on the 16th that their varicella vaccine ‘Varicellaju’ has received product approval from the Drug Administration of Vietnam (DAV).”
“After obtaining domestic approval for Varicellaju in 2020, GC Green Cross acquired the WHO (World Health Organization) PQ (Prequalification), and is currently accelerating approvals in individual countries. They are pursuing a ‘two-track strategy’ that involves participating in international procurement auctions and entering individual markets simultaneously.”
“For this product approval, GC Green Cross conducted local clinical trials in Vietnam, proving the vaccine’s safety and immunogenicity. This means they have met the quality standards that align with the recent regulatory tightening by the Vietnamese Ministry of Health. As the varicella vaccine is administered to children, the importance of quality certification is further emphasized.”
“GC Green Cross plans to generate consistent annual revenue by focusing on direct sales through its local subsidiary, considering the vaccine distribution structure in Vietnam, which is predominantly private market-focused.”
“The private vaccine market in Vietnam grew at an annual average of 32% from 2018 to 2021. As of 2021, the private market was worth approximately $300 million (about 420 billion won), with the varicella vaccine accounting for 10% of that. With the rapid growth in demand for private vaccinations, the vaccination rate is steadily increasing.”
“Lee Jae-woo, head of GC Green Cross Development Division, said, ‘This product approval is an achievement that reflects a localization strategy, going beyond simple exports, and will serve as a bridgehead for expanding into the Southeast Asian market. We will strengthen the position of our trusted vaccine brand with clinical and quality standards that meet global standards.'”
“Varicellaju is a live vaccine developed by GC Green Cross using their proprietary ‘MAV/06’ strain. It is characterized by a high virus content and high yield. Notably, it is the world’s first varicella vaccine produced without antibiotics through an aseptic process system.”